Cargando…
Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery
BACKGROUND: Proteins that ‘read’ the histone code are central elements in epigenetic control and bromodomains, which bind acetyl-lysine motifs, are increasingly recognized as potential mediators of disease states. Notably, the first BET bromodomain-based therapies have entered clinical trials and th...
Autores principales: | Zhan, Yanai, Kost-Alimova, Maria, Shi, Xi, Leo, Elisabetta, Bardenhagen, Jennifer P., Shepard, Hannah E., Appikonda, Srikanth, Vangamudi, Bhavatarini, Zhao, Shuping, Tieu, Trang N., Jiang, Shiming, Heffernan, Timothy P., Marszalek, Joseph R., Toniatti, Carlo, Draetta, Giulio, Tyler, Jessica, Barton, Michelle, Jones, Philip, Palmer, Wylie S., Geck Do, Mary K., Andersen, Jannik N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578755/ https://www.ncbi.nlm.nih.gov/pubmed/26396593 http://dx.doi.org/10.1186/s13072-015-0026-4 |
Ejemplares similares
-
Regulation of β-catenin by t-DARPP in upper gastrointestinal cancer cells
por: Vangamudi, Bhavatarini, et al.
Publicado: (2011) -
t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer
por: Vangamudi, Bhavatarini, et al.
Publicado: (2010) -
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma
por: Giuliani, Virginia, et al.
Publicado: (2021) -
Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2
por: Doherty, Joanne, et al.
Publicado: (2022) -
Bromodomains as therapeutic targets
por: Muller, Susanne, et al.
Publicado: (2011)